Meet the First-Place Winner of RESI Boston’s Innovator’s Pitch Challenge: MindLab 

8 Jul

By Caitlin Dolegowski, Marketing Manager, LSN

CaitiMindLab took the top spot in June’s Innovator’s Pitch Challenge (IPC) at RESI Boston, standing out among dozens of early-stage life science companies who pitched to panels of active investor judges. In this brief interview, we speak with the MindLab team about their fundraising goals, experience participating in RESI, and what’s next for the company.

Watch the interview:

Interested in pitching your company at RESI?

Applications are now open for the Innovator’s Pitch Challenge at RESI Boston, September 17, 2025. Selected companies receive full access to the conference, partnering meetings with investors, and exhibit space in the RESI Exhibition Hall. New! The September 2025 IPC Pitch Package now includes an optional second RESI pass at no additional cost, allowing an additional team member to attend and participate in partnering. Apply now!

Apply to Pitch at RESI Boston Sept. 2025

Tags: , , , , , , , ,

Hot Investor Mandate: Subsidiary of China-Based Enterprise Partners With and Invests in Clinical-Stage Biotech and R&D Enabling Technologies, Investing Up to $100M

1 Jul

A U.S. subsidiary of a China-headquartered enterprise focused on advanced manufacturing and technical services, medical and healthcare, trade, and engineering services. The firm is seeking investment opportunities in life sciences and healthcare. The firm is open to various deal structures, including equity investments, M&A, and joint ventures. 
 

For equity investments, the firm’s sweet spots are Series A and Series B, although the firm is capable of making later-stage investments. Typical check sizes range from $10M to $100M. While primarily focused on opportunities in the U.S., the firm is also open to investments in North and South America. 
 
The firm is most interested in biotech therapeutics and pharmaceuticals and remains opportunistic regarding modalities and indications. The firm typically evaluates assets in Phase I or Phase II. Other areas of interest include hospital products, especially those leveraging AI, as well as surgical tools and R&D research technologies. 
 
The firm does not have specific requirements for a company’s founding team. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Private Investment Firm Seeks Seed-Stage Investment Opportunities in Medical Devices and Digital Health Across the Globe

1 Jul

A privately funded investment firm based in Canada is focused on making direct investments in the following business sectors: medical technology, medical clinics, healthcare IT and healthcare real estate.  In medtech, the firm seeks to invest in seed stage companies.  The firm looks to partner and fund scientific founders to launch a new company and will primarily invest in the seed stage round. The firm typically allocates $100K-$200K, and will syndicate with other investors outside of their region to invest in larger rounds of $500K or more. The firm has physician, medical experience, particularly in the surgical field. The firm invests globally and is currently seeking new investment opportunities. 
 
In the life sciences, the firm is currently seeking to invest in medical devices and healthcare IT. The firm is opportunistic in terms of the class of device and indications, and has particular interest in surgical devices and tools. The firm is additionally interested in digital health, especially those with a software component. The firm prefers to invest in the pre-prototype stage and with particular preference to very early-stage preclinical technology. 
 
The firm is seeking startups with a maximum $5M pre-money valuation and will invest in pre-revenue companies. The firm is very hands-on after an investment, opening up and bringing their network to their portfolio companies. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Venture Arm of Foundation Invests in Seed to Series A Life Science Technologies that Address Brain Cancer and Adjacent CNS Diseases

1 Jul

A private family foundation dedicated to advancing brain tumor research employs a venture philanthropy investment model, which combines deep disease-focused expertise with funding for high-risk/high-reward opportunities. The foundation’s fund typically participates in seed to series A financing rounds with initial investment ranging from $250K to $1M and potential for follow-on investments. The fund is looking to make 3-5 investments per year, primarily within the US and Canada. As a subsidiary of the foundation, the fund will leverage the extensive network and expertise of the foundation and is active in supporting their portfolio companies. The fund does not typically lead rounds and more often co-invests. 
 
The fund focuses on primarily on brain tumor and will consider all technology types, including therapeutics, medical devices, and diagnostics. The fund will also consider adjacent spaces such as neuroscience, as long as there are potential implementations in brain cancer. The fund is also open to talking with companies that do not have a pipeline in brain cancer currently but have potential application in brain cancer in the future. The fund seeks to make investments that are impactful for the company, and typically prefers companies in pre-clinical or early clinical stages, especially for therapeutics. For diagnostics, the fund may consider assets that are in later stages of clinical development. 
 
An ideal founding team will have complementary skill sets, and expertise on the business or the fundraising front is a plus. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Pre-Seed and Seed Stage Focused Fund Seeks USA-Based Medical Device and Digital Health Technologies in Cardiology, Women’s Health, and More

1 Jul

A US-based venture fund invests only in seed and pre-seed rounds, and focuses solely on opportunities in healthcare IT, medtech and consumer health. The firm primarily invests in U.S. based companies but can invest in any geography. 
 
The firm invests in very early stage companies across the healthcare innovation ecosystem, including healthcare IT, medical devices, and consumer health. The firm is highly interested in preventative healthcare, future of work and healthcare IT applications. The firm is open to investing in any area of medicine, but has specific interest in opportunities in cardiology, pulmonary diseases, diabetes, and women’s health. 
 
The firm does not invest in companies that have already raised over $5 million in dilutive capital. The firm seeks to invest in high quality management teams, and prefers to work with experienced entrepreneurs that have a proven track record in their sector. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Announcing Premier PLUS for RESI Partnering  

1 Jul

By Max Braht, Director of Business Development, LSN

Max-Braht-HeadshotPre-pandemic I came across a survey that went out to in-licensors and investors to see from where they sourced their deals. Pipeline databases? Literature? Partnering meetings? Medical conferences? Incoming email solicitations? Website submissions? Warm intros? As it happens, the #1 answer was partnering events, representing the first point of contact for the two parties that eventually made a deal. Even the BioNTech and Pfizer deal came out of a partnering conference in 2013.

However, partnering conferences require a lot of targeted effort in the partnering system to reach out to potential partners and follow-up on the initial outreach. For many early-stage life science entrepreneurs, preparing for a RESI Conference means juggling multiple priorities — investor research, updating pitch decks, team coordination, and most importantly, the execution of your investor outreach strategy.

Many entrepreneurs underestimate the time and effort it takes to identify the right targets, write effective messages, and follow up with these targets consistently. Without a strategic approach, it’s easy to miss out on valuable meetings.

To address this, LSN is introducing a new service: Premier PLUS Partnering, where we do the partnering for you.

Premier PLUS Partnering provides hands-on support from the LSN team to manage your partnering outreach from start to finish.

Drawing on years of experience helping thousands of companies connect with investors, LSN can assist by:

  • Identifying and reaching out to relevant investors and partners
  • Crafting consistent, professional messages tailored to each contact
  • Managing communication and scheduling through the partnering platform
  • Ensuring confirmed meetings in advance of the conference

For entrepreneurs who know the importance of effective partnering strategies and are interested in taking advantage of Premier PLUS Partnering at RESI Boston September, please reach out directly to the LSN team at sales@lifesciencenation.com or include the add-on in your RESI Boston September Registration.

Tags: , , , , , , , ,

New Aging & Longevity Track Launches at RESI Boston via Partnership Between Longevity Global and Life Science Nation 

1 Jul

By Matt Stanton, VP Sales US West, Central and South America, LSN

Longevity Global (LG) and Life Science Nation (LSN) are proud to announce a new partnership to launch a dedicated Aging & Longevity Track at the upcoming RESI (Redefining Every Stage of Investments) Boston Conference this September. This collaboration brings together two leading organizations committed to advancing innovation in healthcare and biotech, positioning longevity-focused startups at the center of global investor and partner engagement.

The Aging & Longevity Track will serve as a curated platform for Longevity Global’s community of founders, researchers, and entrepreneurs to connect with LSN’s expansive partnering ecosystem, including global capital investors and licensing partners. Participating companies will gain access to panels, workshops, educational sessions, and networking opportunities tailored to early-stage ventures across the healthcare spectrum. Longevity Global attendees will also have the option to upgrade to RESI’s renowned one-on-one partnering platform, which allows them to connect directly with strategic partners and capital sources.

“This collaboration gives our longevity ecosystem direct access to global capital and strategic relationships that can accelerate the path from research to real-world impact,” said Christin Glorioso, Founder and CEO at Longevity Global. “The opportunity to plug into RESI’s cross-sector audience while bringing aging science to the forefront is a huge step forward for our mission.”

LSN also views this partnership as a powerful gateway to expand its reach within the rapidly growing longevity sector. “Longevity is one of the most promising frontiers in healthcare, and we’re excited to help emerging companies in this space connect with the capital and partners they need to scale,” said Dennis Ford, CEO of Life Science Nation. “Partnering with Longevity Global allows us to provide a highly curated experience that meets the needs of this evolving vertical.”

About Longevity Global
Longevity Global is a mission-driven community and event platform that connects scientists, startups, and investors working to solve aging. As a branch of Academics for the Future of Science, a 501(c)(3) nonprofit, LG curates events and programs across San Francisco, New York, Boston, the UAE, and beyond.

About Life Science Nation & RESI
Life Science Nation (LSN) is a global partnering platform for every stage of life science companies, offering a suite of tools that includes a database of over 6,000 investors, RESI partnering conferences, and commercialization support. RESI events connect startups with investors and strategic partners across drugs, devices, diagnostics, and digital health.

For more information about RESI Boston September 2025 conferences, contact us at resi@lifesciencenation.com.

Tags: , , , , , , , ,

← Older Entries
Newer Entries →